A Phase 4 interventional study of Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) in Non ST-elevation Myocardial Infarction, sponsored by AstraZeneca. Completed at 13 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-15.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction
This study will be conducted in approximately 8 investigational centres in Taiwan. It is expected that approximately 100 patients will be enrolled into study treatment. This study is to describe the safety and tolerability of ticagrelor, by assessment of the bleeding events and other serious adverse events (SAEs) during 1year follow up in Taiwanese non ST-elevation myocardial infarction (NSTEMI) patients.
286 studies on the registry are indexed under Non-ST Elevated Myocardial Infarction; 52 are open to participants now.
This study's enrollment of 108 is below the median of 244 across 146 interventional studies indexed under Non-ST Elevated Myocardial Infarction.
Browse Non-ST Elevated Myocardial Infarction studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Drug page: Ticagrelor
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Also known as: "Brilinta"
Number of Participants With Fatal/Life-threatening Bleedings
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings
Time frame: during 1year follow up with ticagrelor treatment
Number of Participants With Bleeding Events (Major Bleedings)
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings
Time frame: during 1year follow up with ticagrelor treatment
Number of Participants With Bleeding Events (Major and Minor Bleedings)
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings
Time frame: during 1year follow up with ticagrelor treatment
Number of Participants With Other Serious Adverse Event (SAEs)
Evaluation of serious adverse events other than bleedings
Time frame: during 1year follow up with ticagrelor treatment
Number of Participants With Major Cardiovascular Events
Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke
Time frame: during 1year follow up with ticagrelor treatment
This study was conducted at 13 centres in Taiwan. The first patient was enrolled on 23 April 2015 and the last visit of the last patient took was on 9 February 2017. Informed consent was received for 113 patients
| Milestone | Single Arm |
|---|---|
| Started | 108 |
| Completed | 99 |
| Not completed | 9 |
| Withdrew: Death | 7 |
| Withdrew: Withdrawal by subject | 2 |
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings
| Participants | Single Arm |
|---|---|
| Fatal/life-threatening bledings | 4 |
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings
| Participants | Single Arm |
|---|---|
| Major bleedings | 7 |
Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings
| Participants | Single Arm |
|---|---|
| Major and minor bleedings | 20 |
Evaluation of serious adverse events other than bleedings
| Participants | Single Arm |
|---|---|
| Serious adverse events other than bleeding | 21 |
Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke
| Participants | Single Arm |
|---|---|
| Composite of major cardiovascular events | 6 |
Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. 1year if the participant completed treatment according to the study plan. All-cause mortality is collected during 1 year follow-up, including deaths that occur more than 7 days after last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm | 7/108 (6.5%) | 23/108 (21.3%) | 45/108 (41.7%) |
| Event | Single Arm |
|---|---|
| PneumoniaInfections and infestations | 4/108 |
| Angina pectorisCardiac disorders | 2/108 |
| SepsisInfections and infestations | 1/108 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/108 |
| Haemorrhagic transformation strokeNervous system disorders | 1/108 |
| GlaucomaEye disorders | 1/108 |
| VertigoEar and labyrinth disorders | 1/108 |
| Acute coronary syndromeCardiac disorders | 1/108 |
| Acute myocardial infarctionCardiac disorders | 1/108 |
| Cardiogenic shockCardiac disorders | 1/108 |
| Event | Single Arm |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 10/108 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/108 |
| EcchymosisSkin and subcutaneous tissue disorders | 10/108 |
| HypokalaemiaMetabolism and nutrition disorders | 8/108 |
| ContusionInjury, poisoning and procedural complications | 7/108 |
| Angina pectorisCardiac disorders | 6/108 |
| DiarrhoeaGastrointestinal disorders | 6/108 |
| HyperuricaemiaMetabolism and nutrition disorders | 6/108 |
| PyrexiaGeneral disorders | 6/108 |
| Urinary tract infectionInfections and infestations | 6/108 |
| Age, Continuous(years) | Single Arm |
|---|---|
| Mean | 61.7 ± 12.12 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 22 |
| Male | 86 |
| Race/Ethnicity, Customized(Participants) | Single Arm |
|---|---|
| Asian | 108 |
| Race/Ethnicity, Customized(Participants) | Single Arm |
|---|---|
| Not hispanic or latino | 108 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in Feb 2017, 21 months.
Results were first posted in Oct 2018, 1 year 8 months after primary completion.
Of 23 phase 4 interventional studies under Non-ST Elevated Myocardial Infarction, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 74. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor
Non-ST Elevated Myocardial Infarction →